ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo

Abstract

Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease caused by the fungus Aspergillus fumigatus, and is a leading cause of invasive fungal infection-related mortality and morbidity in patients with hematological malignancies and bone marrow transplants. We developed and tested a novel probe for noninvasive detection of A. fumigatus lung infection based on antibody-guided positron emission tomography and magnetic resonance (immunoPET/MR) imaging. Administration of a [

Immunoproteomics of Aspergillus for the development of biomarkers and immunotherapies

“…The antigen is released by growing hyphae during infection and can be detected in body fluids. Recently, a novel positron emission tomography (PET) tracer based on JF5 was developed for the detection of A. fumigatus lung infections by means of antibody-guided PET and magnet resonance (immunoPET/MR) imaging [97].…”

The Promise of Molecular Imaging in the Study and Treatment of Infectious Diseases

“…F-18 analogs of trehalose have also been developed as potential imaging agents for mycobacteria [37], while Aspergillus fumigatus has been imaged in vivo using Ga-68-radiolabeled siderophores [38]. Investigators have also utilized radiolabeled antibodies to image A. fumigatus and Yersinia in murine models [39,40]. Similarly, Santangelo et al developed a technique to image simian immunodeficiency virus (SIV) replication using a Cu-64-labeled SIV Gp120-specific antibody and were able to detect virus-specific PET signals in treated and untreated monkeys [41].…”

Editor’s choice: recent research highlights from the International Journal of Nanomedicine

“…Nanomedicine 1 has increasingly received a tremendous attention over the past two decades as a potential multidimensional field, developing nano-applications that are transforming a host of medical products and services, 2,3 including drug delivery 4 and health-monitoring devices, and the possibility of gaining new insights about "undruggable targets" and treatment through atomic-scale precision is increasing rapidly. 5 Although it is uncertain as to which of the new delivery platforms will become the most effective and useful, it is certain that many new approaches will be investigated in the years to come. 4,6 In one of the recent issues of the International Journal of Nanomedicine, Thakur et al investigated the systemic toxicity of nanoengineered chitosan-solid lipid particles encapsulated with aspirin and curcumin in combination with free sulforaphane (ACS c-SLNs) in BALB/c mice, which is a very elaborative study using an animal model with the capability to address how the benefits of new drug delivery approaches could be achieved while minimizing potential risks.…”